PENTAX Medical Announces Sale of C2 CryoBalloon™ Product Line to Merit Medical Systems through Asset Purchase Agreement
PENTAX Medical announced on October 15, 2025 an asset purchase agreement selling the C2 CryoBalloon™ technology to Merit Medical Systems (NASDAQ: MMSI). The C2 CryoBalloon, part of PENTAX Medical's therapeutic portfolio since 2017, provides controlled cryotherapy for Barrett's Esophagus and related GI disorders.
Under the agreement, Merit will integrate C2 into its Endoscopy portfolio, transfer product manufacturing to its facility in South Jordan, Utah, and hire several PENTAX Medical employees to support continuity. PENTAX Medical said the sale lets it sharpen focus on its core business of flexible reusable endoscopy and deepen clinical partnerships.
PENTAX Medical ha annunciato il 15 ottobre 2025 un accordo di acquisto di asset che vende la tecnologia C2 CryoBalloon™ a Merit Medical Systems (Nasdaq: MMSI). Il C2 CryoBalloon, parte del portafoglio terapeutico di PENTAX Medical dal 2017, fornisce crioterapia controllata per Barrett esofago e disturbi GI correlati.
Secondo l'accordo, Merit integrerà il C2 nel proprio portafoglio Endoscopia, trasferirà la produzione dei prodotti nel suo impianto di South Jordan, Utah e assumerà diversi dipendenti di PENTAX Medical per garantire la continuità. PENTAX Medical ha dichiarato che la vendita le permetterà di affinare il focus sul suo core business di endoscopia flessibile riutilizzabile e di approfondire le partnership cliniche.
PENTAX Medical anunció el 15 de octubre de 2025 un acuerdo de compra de activos para vender la tecnología C2 CryoBalloon™ a Merit Medical Systems (NASDAQ: MMSI). El C2 CryoBalloon, parte del portafolio terapéutico de PENTAX Medical desde 2017, proporciona crioterapia controlada para Barrett esófago y trastornos GI relacionados.
Según el acuerdo, Merit integrará el C2 en su portafolio de Endoscopia, transferirá la fabricación de productos a su instalación en South Jordan, Utah y contratará a varios empleados de PENTAX Medical para apoyar la continuidad. PENTAX Medical dijo que la venta le permitirá enfocarse más en su negocio principal de endoscopia reutilizable flexible y profundizar las asociaciones clínicas.
PENTAX Medical가 2025년 10월 15일에 Merit Medical Systems(NASDAQ: MMSI)에 C2 CryoBalloon™ 기술을 매각하는 자산 매매 계약을 발표했습니다. 2017년부터 PENTAX Medical의 치료 포트폴리오의 일부인 C2 CryoBalloon은 Barrett 식도 및 관련 GI 질환에 대한 제어된 냉각 치료를 제공합니다.
계약에 따라 Merit는 C2를 자사의 Endoscopy 포트폴리오에 통합하고, 생산을 유타주 사우스조던의 시설로 이전하며, 연속성 지원을 위해 PENTAX Medical의 다수 직원들을 채용할 것입니다. PENTAX Medical은 매각이 유연한 재사용 가능 내시경이라는 핵심 비즈니스에 집중하고 임상 파트너십을 심화하는 데 도움이 될 것이라고 밝혔습니다.
PENTAX Medical a annoncé le 15 octobre 2025 un accord d'achat d'actifs vendant la technologie C2 CryoBalloon™ à Merit Medical Systems (NASDAQ : MMSI). Le C2 CryoBalloon, faisant partie du portefeuille thérapeutique de PENTAX Medical depuis 2017, offre une cryothérapie contrôlée pour l'œsophage de Barrett et les troubles GI associés.
Sous l'accord, Merit intégrera le C2 dans son portefeuille Endoscopie, transférera la fabrication des produits vers son installation à South Jordan, Utah et recrutera plusieurs employés de PENTAX Medical pour assurer la continuité. PENTAX Medical a déclaré que la vente lui permettrait de recentrer ses activités sur son cœur de métier de endoscopie réutilisable flexible et d'approfondir les partenariats cliniques.
PENTAX Medical hat am 15. Oktober 2025 eine Vereinbarung zum Vermögensankauf angekündigt, die die C2 CryoBalloon™-Technologie an Merit Medical Systems (NASDAQ: MMSI) verkauft. Der C2 CryoBalloon ist seit 2017 Teil des therapeutischen Portfolios von PENTAX Medical und bietet kontrollierte Kryotherapie für Barrett-Ösophagus und verwandte GI-Störungen.
Nach der Vereinbarung wird Merit C2 in sein Endoskopie-Portfolio integrieren, die Herstellung der Produkte in seine Einrichtung in South Jordan, Utah verlagern und mehrere Mitarbeiter von PENTAX Medical zur Sicherstellung der Kontinuität einstellen. PENTAX Medical erklärte, der Verkauf ermögliche es, sich stärker auf das Kerngeschäft flexible wiederverwendbare Endoskope zu konzentrieren und klinische Partnerschaften zu vertiefen.
PENTAX Medical أعلنت في 15 أكتوبر 2025 عن اتفاقية شراء أصول لبيع تكنولوجيا C2 CryoBalloon™ إلى Merit Medical Systems (المدرجة في NASDAQ: MMSI). يعتبر C2 CryoBalloon، جزءاً من محفظة PENTAX Medical العلاجية منذ 2017، تكنولوجيا التبريد المعتمد للتحكم للعلاج من Barrett في المريء والاضطرابات المعوية ذات الصلة.
وبموجب الاتفاق، ستدمج Merit C2 في محفظة الإندوسكوبيا الخاصة بها، وستنقل تصنيع المنتج إلى منشأتها في South Jordan, Utah وستوظف عدداً من موظفي PENTAX Medical لدعم الاستمرارية. قالت PENTAX Medical إن البيع سيمكنها من تركيز أنشطتها الأساسية على الإندوسكوبيا المرنة القابلة لإعادة الاستخدام وتعميق الشراكات klinية.
PENTAX Medical 于 2025年10月15日 宣布了一项资产购买协议，将 C2 CryoBalloon™ 技术出售给 Merit Medical Systems（纳斯达克股票代码：MMSI）。自 2017 年以来，C2 CryoBalloon 作为 PENTAX Medical 的治疗组合部分，为巴雷特食管及相关 GI 疾病提供可控低温治疗。
根据协议，Merit 将把 C2 纳入其内镜学产品组合，将产品制造转移到其位于 South Jordan, Utah 的工厂，并招聘多名 PENTAX Medical 员工以支持连续性。PENTAX Medical 表示，此次出售将使其将重点放在 灵活的可重复使用内镜 的核心业务上，并深化临床伙伴关系。
- Transaction announced on October 15, 2025
- C2 CryoBalloon in PENTAX portfolio since 2017
- Manufacturing transfer to Merit facility in South Jordan, Utah
- Several employees to join Merit for continuity
- PENTAX refocus on flexible reusable endoscopy
- PENTAX divests the C2 CryoBalloon therapeutic product line
- Product manufacturing will move away from PENTAX-controlled sites
Insights
Asset sale transfers C2 CryoBalloon™ to Merit while PENTAX refocuses on core endoscopy.
Merit Medical will acquire the C2 CryoBalloon™ technology from PENTAX Medical under an asset purchase agreement announced on
The business effect is straightforward: PENTAX narrows its strategic scope to flexible reusable endoscopy, while Merit expands its endoscopy portfolio and customer reach. Key dependencies include the successful physical transfer of manufacturing, integration of personnel, and the pace of clinical adoption for Barrett’s Esophagus and chronic GERD treatments. Watch the announced timeline for the "over the coming months" manufacturing move, confirmation of regulatory or quality-transfer milestones, and any statements about volume or commercialization plans from Merit.
Near term, monitor operational handover milestones and continuity of supply; medium term, watch adoption metrics and any product integration announcements from Merit. Given only the facts disclosed, the transaction is neutral from an impact standpoint because it is a portfolio realignment without disclosed financial terms or explicit market guidance.
Transaction supports PENTAX Medical's strategic focus on core flexible reusable endoscopy
This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships.
The C2 CryoBalloon™ has been part of PENTAX Medical's therapeutic portfolio since 2017, offering a minimally invasive option to treat patients suffering from Barrett's Esophagus and other gastrointestinal disorders. The minimally invasive device delivers controlled cryotherapy to ablate unwanted tissue while preserving surrounding structures. Under Merit Medical's stewardship, the technology is expected to reach new levels of adoption and impact, expanding access to care for patients suffering from chronic GERD and related conditions.
"C2 technology has been an exciting part of our innovation journey," said Dominique Vincent, President of PENTAX Medical. "We are proud of the clinical value it has delivered and are confident that Merit Medical, with its expanding footprint in upper GI treatments and deep expertise in therapeutic endoscopy, is ideally positioned to unlock the full potential of C2. This transition allows PENTAX Medical to refocus on our core strength—flexible reusable endoscopy—and continue delivering intuitive solutions that empower clinicians worldwide."
Merit Medical will integrate the C2 CryoBalloon™ into its Endoscopy portfolio, complementing its existing products and customer base. Over the coming months, product manufacturing will be transferred to Merit's facility in
The agreement reinforces PENTAX Medical's strategic focus on its core strength—flexible reusable endoscopy—and its commitment to delivering intuitive solutions that empower clinicians worldwide.
About PENTAX Medical
PENTAX Medical, a division of the HOYA Group, is a global player in flexible, reusable endoscopy solutions. The company develops, manufactures, distributes, and services endoscopic equipment worldwide. PENTAX Medical is committed to delivering intuitive, flexible endoscopy solutions that empower healthcare professionals to provide outstanding care. Its mission is to maintain product excellence while collaborating closely with clinical partners to understand and address their daily challenges, workflows, and goals. At the core of this mission is a commitment to reliability and high-quality imaging—fundamental requirements for clinical performance. Building on this foundation, PENTAX Medical delivers solutions that integrate seamlessly into clinical practice, supported by ergonomic and ease-of-use innovations, practical clinical education, and personalized, attentive customer support.
For more information, please visit our website: https://www.pentaxmedical.com.
About Merit Medical
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.
About HOYA
HOYA Corporation, founded in
View original content:https://www.prnewswire.com/news-releases/pentax-medical-announces-sale-of-c2-cryoballoon-product-line-to-merit-medical-systems-through-asset-purchase-agreement-302585187.html
SOURCE PENTAX Medical
FAQ
What did PENTAX Medical announce about the C2 CryoBalloon on October 15, 2025?
How will the C2 CryoBalloon transition affect manufacturing and staff?
Why did PENTAX Medical sell the C2 CryoBalloon to Merit Medical (MMSI)?
What clinical uses does the C2 CryoBalloon serve and how long was it with PENTAX?
What does the acquisition mean for Merit Medical (MMSI)?
